HRP20150317T1 - Peptidi trave za cjepivo - Google Patents

Peptidi trave za cjepivo Download PDF

Info

Publication number
HRP20150317T1
HRP20150317T1 HRP20150317TT HRP20150317T HRP20150317T1 HR P20150317 T1 HRP20150317 T1 HR P20150317T1 HR P20150317T T HRP20150317T T HR P20150317TT HR P20150317 T HRP20150317 T HR P20150317T HR P20150317 T1 HRP20150317 T1 HR P20150317T1
Authority
HR
Croatia
Prior art keywords
segment
polypeptide consisting
polypeptide
preparation
administration
Prior art date
Application number
HRP20150317TT
Other languages
English (en)
Croatian (hr)
Inventor
Rod Hafner
Paul Laidler
Guy Layton
Mark Larche
Original Assignee
Circassia Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0901927.4A external-priority patent/GB0901927D0/en
Priority claimed from GB0901928A external-priority patent/GB0901928D0/en
Priority claimed from GB0912578A external-priority patent/GB0912578D0/en
Priority claimed from PCT/GB2009/001995 external-priority patent/WO2010018384A1/en
Priority claimed from GB0917871A external-priority patent/GB0917871D0/en
Application filed by Circassia Limited filed Critical Circassia Limited
Publication of HRP20150317T1 publication Critical patent/HRP20150317T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
HRP20150317TT 2009-02-05 2010-02-05 Peptidi trave za cjepivo HRP20150317T1 (hr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB0901927.4A GB0901927D0 (en) 2009-02-05 2009-02-05 Peptide for IL10 production
GB0901928A GB0901928D0 (en) 2009-02-05 2009-02-05 Peptides for vaccine
GB0912578A GB0912578D0 (en) 2009-07-20 2009-07-20 Peptide for IL-10 production
PCT/GB2009/001995 WO2010018384A1 (en) 2008-08-15 2009-08-14 T-cell antigen peptide from allergen for stimulation of il-10 production
GB0917871A GB0917871D0 (en) 2009-10-12 2009-10-12 Peptides for vaccine
EP10704399.4A EP2393830B8 (en) 2009-02-05 2010-02-05 Grass peptides for vaccine
PCT/GB2010/000198 WO2010089554A1 (en) 2009-02-05 2010-02-05 Peptides for vaccine

Publications (1)

Publication Number Publication Date
HRP20150317T1 true HRP20150317T1 (hr) 2015-04-24

Family

ID=42082585

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150317TT HRP20150317T1 (hr) 2009-02-05 2010-02-05 Peptidi trave za cjepivo

Country Status (23)

Country Link
US (2) US8753644B2 (enExample)
EP (2) EP2393830B8 (enExample)
JP (2) JP5746053B2 (enExample)
KR (1) KR20110111307A (enExample)
CN (2) CN102307893B (enExample)
AU (1) AU2010212193B2 (enExample)
BR (1) BRPI1008802A2 (enExample)
CA (1) CA2751500A1 (enExample)
DK (1) DK2393830T3 (enExample)
EA (1) EA020792B1 (enExample)
ES (1) ES2532759T3 (enExample)
GB (1) GB2469894B (enExample)
HK (1) HK1212358A1 (enExample)
HR (1) HRP20150317T1 (enExample)
IL (1) IL214257A (enExample)
MX (1) MX2011008179A (enExample)
NZ (1) NZ594268A (enExample)
PL (1) PL2393830T3 (enExample)
PT (1) PT2393830E (enExample)
SG (1) SG173523A1 (enExample)
SI (1) SI2393830T1 (enExample)
WO (1) WO2010089554A1 (enExample)
ZA (1) ZA201105436B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2393830T1 (sl) * 2009-02-05 2015-04-30 Circassia Limited Travni peptidi za cepivo
CN107320734A (zh) * 2011-04-29 2017-11-07 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
CN105307641A (zh) 2013-05-03 2016-02-03 西莱克塔生物科技公司 用于降低不期望体液免疫应答的给药组合
EA201790551A1 (ru) 2014-09-07 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору
WO2017004561A1 (en) 2015-07-01 2017-01-05 Alk-Abelló A/S Peptide combinations and uses thereof for treating grass allergy
EP4599848A3 (en) 2017-03-11 2025-12-03 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
EP3672600A4 (en) 2017-08-21 2021-05-19 Glycom A/S SYNTHETIC COMPOSITION TO REDUCE ALLERGY SYMPTOMS
CN108802216B (zh) * 2018-05-23 2021-04-16 山东出入境检验检疫局检验检疫技术中心 一种使用区域敏感性蛋白组和/或多肽组鉴别刺参产地的方法
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340729C (en) 1988-03-23 1999-09-07 Mohan Bir Singh Ryegrass pollen allergen
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
CA2089735C (en) 1990-08-17 2008-03-18 Mohan Bir Singh Ryegrass pollen allergen
WO1992016554A1 (en) 1991-03-14 1992-10-01 The University Of Melbourne Protein allergens of the species cynodon dactylon
WO1994001560A1 (en) 1991-07-12 1994-01-20 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
EP0665888B2 (en) 1991-08-16 2007-07-25 The University Of Melbourne Ryegrass pollen allergen
EP0668915A1 (en) 1991-11-15 1995-08-30 The University Of Melbourne Protein allergens of the species cynodon dactylon
US6441157B1 (en) 1991-11-15 2002-08-27 University Of Melbourne Nucleic acid sequences encoding protein allergens of the species Cynodon dactylon
ATE283281T1 (de) 1992-08-14 2004-12-15 Univ Melbourne T-zell epitope des raygraspollen-allergens
US5480972A (en) 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen
US6214358B1 (en) 1992-10-30 2001-04-10 Immulogic Pharamaceutical Corp. Protein allergens of the species Cynodon dactylon
NZ263913A (en) * 1993-03-12 1997-10-24 Immulogic Pharma Corp Lol pi protein allergen from ryegrass and related peptides coding sequences, vectors, protein production and use
FI960629L (fi) * 1993-08-13 1996-04-12 Immulogic Pharma Corp Raiheinäsiitepöly allergeenin T-soluepitoopit
US5968526A (en) 1994-04-14 1999-10-19 Immulogic Pharamaceutical Corporation T cell epitopes of the major allergens from Dermatophagoides (house dust mite)
GB9412714D0 (en) 1994-06-24 1994-08-17 Lewin Ian V T cill epitopes
AU3338195A (en) * 1994-07-26 1996-02-22 University Of Manitoba Allergen peptides
US7112333B1 (en) 1994-08-05 2006-09-26 Heska Corporation T cell epitopes of ryegrass pollen allergen
IL115744A (en) 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
AT402505B (de) 1995-08-02 1997-06-25 Biomay Prod & Handel Rekombinantes 60 kda pflanzliches panallergen (kofaktor-unabhängige phosphoglyceratmutase; e.c. 5.4.2.1.)
JP2002500198A (ja) 1998-01-09 2002-01-08 サーカシア リミテッド 脱感作のための方法及び組成物
DE19823097A1 (de) * 1998-05-22 1999-11-25 Max Planck Gesellschaft Mittel gegen saisonale Typ-I-Allergien und bakterielle Infektionen
US6989146B2 (en) 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
AUPR775401A0 (en) * 2001-09-18 2001-10-11 Monash University Novel Epitopes and Uses Thereof
WO2003047618A2 (en) 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
AUPS148202A0 (en) 2002-04-02 2002-05-09 Monash University Immunotherapeutic and immunoprophylactic reagents
AU2003228133A1 (en) 2002-04-22 2003-11-03 Umc Utrecht Holding B.V. Reduction of unwanted immune reactions
GB0210741D0 (en) 2002-05-10 2002-06-19 Medical Res Council Methods of therapy
GB0308988D0 (en) 2003-04-17 2003-05-28 Univ Singapore Molecule
DE102004035337A1 (de) * 2004-07-21 2006-03-16 Merck Patent Gmbh Varianten der Gruppe 1-Allergene aus Poaceae mit reduzierter Allergenität und erhaltener T-Zellreaktivität
WO2006075253A2 (en) 2005-01-11 2006-07-20 Commissariat A L'energie Atomique Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides.
WO2006132607A1 (en) 2005-06-10 2006-12-14 National University Of Singapore Mutant allergen(s)
DE202005009990U1 (de) * 2005-06-25 2006-11-02 Hengst Gmbh & Co.Kg Vorrichtung zum Abscheiden von Ölteilchen aus dem Kurbelgehäuseentlüftungsgas einer Brennkraftmaschine
US20070092532A1 (en) 2005-10-25 2007-04-26 Board Of Trustees Operating Michigan State University Arthritis vaccines and methods
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
US20110038881A1 (en) 2007-05-09 2011-02-17 Circassia Limited Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
BRPI0815395A2 (pt) 2007-08-15 2015-02-10 Circassia Ltd Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
EP2042193A1 (en) 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
US8821887B2 (en) 2008-08-15 2014-09-02 Circassia Limited T-cell antigen peptide from allergen for stimulation of IL-10 production
SI2393830T1 (sl) * 2009-02-05 2015-04-30 Circassia Limited Travni peptidi za cepivo

Also Published As

Publication number Publication date
PL2393830T3 (pl) 2015-07-31
US8753644B2 (en) 2014-06-17
IL214257A (en) 2016-06-30
JP2012516693A (ja) 2012-07-26
EP2393830B8 (en) 2015-03-18
JP5746053B2 (ja) 2015-07-08
ES2532759T3 (es) 2015-03-31
WO2010089554A1 (en) 2010-08-12
CN103784952A (zh) 2014-05-14
SG173523A1 (en) 2011-09-29
CA2751500A1 (en) 2010-08-12
WO2010089554A8 (en) 2011-10-06
BRPI1008802A2 (pt) 2016-03-08
HK1212358A1 (en) 2016-06-10
US20140302071A1 (en) 2014-10-09
AU2010212193B2 (en) 2015-05-14
PT2393830E (pt) 2015-04-23
EP2393830B1 (en) 2015-01-28
MX2011008179A (es) 2011-09-09
CN102307893A (zh) 2012-01-04
CN103784952B (zh) 2016-08-17
SI2393830T1 (sl) 2015-04-30
EA020792B1 (ru) 2015-01-30
KR20110111307A (ko) 2011-10-10
EA201171001A1 (ru) 2012-02-28
NZ594268A (en) 2013-05-31
GB2469894B (en) 2011-09-07
ZA201105436B (en) 2012-09-26
AU2010212193A1 (en) 2011-08-18
DK2393830T3 (en) 2015-04-27
CN102307893B (zh) 2014-03-26
EP2393830A1 (en) 2011-12-14
US20120148612A1 (en) 2012-06-14
GB2469894A (en) 2010-11-03
JP6215252B2 (ja) 2017-10-18
IL214257A0 (en) 2011-09-27
EP2891662A1 (en) 2015-07-08
JP2015180646A (ja) 2015-10-15
GB201001954D0 (en) 2010-03-24

Similar Documents

Publication Publication Date Title
HRP20171909T1 (hr) Postupci i sastavi za otkrivanje razine djelovanja lizosomalne eksocitoze i načini njihove uporabe
JP2015517488A5 (enExample)
ME02662B (me) Niskofrekventna terapija glatiramer acetatom
HRP20220717T1 (hr) Modificirani pripravci mrna
AR093481A1 (es) Parche de varios dias para la administracion transdermica de rotigotina
JP2011241213A5 (enExample)
WO2015024667A8 (en) Method for increasing expression of rna-encoded proteins
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
AR082189A1 (es) Formas de dosificacion gastrorretentivas, procedimiento
CA2817787C (en) Composition comprising a peptide and an inhibitor of viral neuraminidase
RU2011105821A (ru) Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности
BR112014008036A2 (pt) tratamento de rinite
Li et al. Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic
RU2018120387A (ru) Ангиотензин в лечении состояний головного мозга
RU2016114098A (ru) Новое производное аналога инсулина
MX353649B (es) Proteinas protozoarias variables de superficie (vsp) como vehiculos para la administracion de farmacos.
NZ594268A (en) Grass peptides for vaccine
HRP20160481T1 (hr) Peptidi za cjepiva protiv alergije na brezu
WO2013021284A3 (en) Anti-il-6 vaccine composition
JP2016515137A5 (enExample)
JP2017517561A5 (enExample)
HRP20170794T1 (hr) Izvedeni peptidi faktora viii za upotrebu u liječenju hemofilije a
AR087034A1 (es) Compuestos y combinaciones farmaceuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas
WO2010086867A3 (en) Peptides, pharmaceutical compositions comprising same and uses thereof